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The nucleotide sequence of a highly pathogenic porcine reproductive and respiratory syndrome virus (PRRSV) was determined.
Transfection of MARC-145 cells with capped in vitro transcripts derived from a full-length cDNA clone of the viral genome resulted in
infectious PRRSV with growth characteristics similar to that of the parental virus. Primer extension analysis revealed that during replication,
the viral polymerase corrected the two nonviral guanosine residues present at the 5V terminus of the transfected transcripts. Animal studies
showed that the cloned virus induced hyperthermia, persistent viremia, and antibody response, similar to that observed with the parental
virus. Contact transmission occurred rapidly within 3 days of introduction of naı¨ve pigs into the group of clone virus-inoculated pigs. These
results suggest that the cloned virus retains the in vivo virulence and contagion properties of the parental virus, thus, providing the
background for reverse genetics manipulation in systematic examination of attenuation and virulence phenotypes.
D 2004 Elsevier Inc. All rights reserved.Keywords: PRRSV; Nucleotide sequence; Full-length cDNA; In vitro transcripts; Transfection; MARC-145 cells; Primer extension; PRRSV pathogenesisIntroduction
Porcine reproductive and respiratory syndrome virus
(PRRSV) is a spherical, enveloped virus, which causes
highly contagious, severe disease in the natural host, the
swine, with a spectrum of disease states ranging from
respiratory failure in neonates to abortions in sows (Chris-
tianson, 1992; Keffaber, 1989). PRRSV is endemic to most
swine producing countries and imposes a heavy economic
burden due to high mortality associated with the disease
(Albina, 1997; Meredith, 1995).
Along with equine arteritis virus, simian hemorrhagic
fever virus, and lactate dehydrogenase-elevating virus,0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.04.046
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E-mail address: apattnaik2@unl.edu (A.K. Pattnaik).PRRSV belongs to the Arteriviridae family (Cavanaugh,
1997; Meulenberg et al., 1993, 1994). Recently, arterivi-
ruses have been classified within the order Nidovirales for
shared strategies of replication and transcription with the
coronaviruses (Cavanaugh, 1997) of which severe acute
respiratory syndrome virus (SARS-CoV) is a member.
PRRSV possesses an approximately 15.4 kb positive
polarity, single-strand RNA genome (Meulenberg et al.,
1993) with a 5V-cap and a 3V-poly(A) tail. The genome is
translationally active and is organized into 5V-terminal
open reading frames (ORFs) encoding nonstructural pro-
teins, ORF1a and ORF1b, which are proteolytically pro-
cessed to generate replicase proteins. The 3V-terminal
ORFs 2–7 encode, in succession, the glycoproteins 2–
5, the matrix (M) protein, and the nucleocapsid (N)
protein. Immediately following release into the cytoplasm,
the genomic RNA is translated into ORF1a and ORF1ab
polyproteins. The latter is translated via a–1 pseudoknot-
mediated ribosomal frameshift. Both ORF1a and ORF1ab
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vidual mature proteins. The viral replicase complex rep-
licates the genomic RNA into a negative-sense
intermediate that in turn serves as the template for
generation of progeny genomic RNA. The replicase also
generates a nested set of negative-sense subgenomic (sg)
RNAs. These sgRNAs (Sawicki and Sawicki, 1990;
Sethna et al., 1989) serve as templates for generation of
5V- and 3V-coterminal positive-sense sgmRNAs encoding
ORF2-7 structural proteins, which participate in viral
assembly and also are responsible for viral antigenicity
(Conzelmann et al., 1993; Meulenberg et al., 1995, 1997).
It is thought that replication and transcription occurs
along double membrane compartments within the host
cell (Pol et al., 1997).
One major step toward understanding PRRSV biology
was achieved through the development of infectious cDNA
clones. In 1998, Meulenberg et al. (1998) reported the
generation of an infectious clone of the European proto-
type Lelystad virus (LV). Recently, the construction of an
infectious clone for the prototypic North American strain,
VR-2332, has been reported (Nielsen et al., 2003). In these
studies, transfection of BHK-21 cells with capped in vitro
transcripts resulted in generation of infectious PRRSV that
could infect permissive CL2621 and MARC-145 cells
(Kim et al., 1993). Although the rescued recombinant
North American virus, VR-2332, exhibited similar growth
properties in MARC-145 cells, its growth, genomic stabil-
ity, and transmission by contact in swine remain largely
unaddressed.
In order to study the mechanisms of replication and
pathogenesis of this important swine pathogen, we used a
highly virulent American PRRSV isolate (NVSL #97-7895)
to construct an infectious cDNA clone. This particular
isolate was obtained in southeastern Iowa from a vaccinated
herd that developed PRRSV infection (Allende et al., 2000).
Initial sequence analyses of limited regions of the viral
genome indicated that it was not a revertant of the vaccine
strains in use at that time and that the isolate represented a
distinct North American virus associated with high patho-
genicity, demonstrated by the abortifacient character of the
isolate in the PRRS experimental model of reproductive
failure (Osorio et al., 2002).
In the current study, we report the complete sequence
analyses of the PRRSV genome. A full-length cDNA
clone representing the consensus amino acid sequence
encoded in the genome was assembled. Capped in vitro
transcripts produced from the full-length cDNA clone,
when transfected into MARC-145 cells, generated PRRSV
with growth kinetics indistinguishable from the parental
virus. More importantly, we demonstrate that the recom-
binant virus replicated in pigs causing clinical signs,
persistent viremia, and high antibody titers against
PRRSV. Furthermore, we show that contact transmission
of the virus from the infected pigs to introduced sentinels
occurred rapidly.Results
Sequence determination of the PRRSV NVSL #97-7895
genome
In January 1997, a swine herd, with a previous history of
vaccination against PRRSV, developed highly lethal, ‘‘atyp-
ical’’ porcine reproductive and respiratory syndrome (Hal-
bur and Bush, 1997). As part of a survey to study the
atypical form of PRRS affecting the region, PRRSV NVSL
#97-7895 was isolated from a newborn pig and passaged on
MARC-145 cells. The passaged virus was purified and
utilized for extraction of the viral genomic RNA and
subsequent sequence determination.
Sequencing of ORF5 led to the conclusion that this virus
varied greatly from the vaccine strain and represented a
unique isolate. To determine the genome sequence of this
PRRSV, we utilized RT-PCR to generate five overlapping
cDNA fragments (amplicons) encompassing the entire
length of the genome (Fig. 1A). These five amplicons (A,
B, 5C, 3C, and D) were individually cloned into the low-
copy plasmid, pBR322. Primers (Table 1) used in amplifi-
cation incorporated specific restriction enzyme sites to
facilitate cloning. The top and bottom strands of 6–12
clones of each amplicon were sequenced. Thus, the consen-
sus sequence was derived for each nucleotide position with
12- to 24-fold redundancy. Additionally, the overlapping
regions between each amplicon, which contained artificial
sequences introduced by primers used in the initial RT-PCR,
were cloned and sequenced similarly with primer pairs
representing the newly determined consensus sequences.
Authentic 5V-terminal sequences of the PRRSV genome
were obtained by RLM-RACE and subsequent sequence
analysis of six individual clones. Amplicon A, which
contained the 5Vend of the genome, was repaired to reflect
the authentic viral sequences.
Final assembly of the full-length consensus sequence of
the PRRSV genome revealed a composition of 15413 nt
with a 5V-untranslated region (UTR) containing 191 nt, two
bases longer than the North American prototype VR-2332
(Genbank, accession #U87392). The genome shares 90–
91% sequence identity with the North American isolates
VR-2332, PA-8, and 16244B. We also observed an approx-
imately equal ratio of serine or leucine at amino acid
position 1028 and proline or serine at position 2783 of the
ORF1ab polyprotein.
Construction of full-length cDNA clone of PRRSV
DNA fragments A and D (Fig. 1A) were ligated using
BsrGI site to obtain the plasmid pAD. Bacteriophage T7
RNA polymerase promoter was introduced at the 5V termi-
nus of the viral genome. Two additional guanosine residues
were introduced between the T7 promoter and the first
nucleotide of the viral genome to facilitate efficient tran-
scription by T7 RNA polymerase. On the basis of the
Fig. 1. Construction of PRRSV NVSL #97-7895 full-length cDNA. (A) Five overlapping regions of the viral genome were amplified to generate the cDNA
fragments A, B, 5C, 3C, and D. Fragment D was amplified to introduce 41 adenosines at the 3V terminus. The T7 RNA polymerase promoter (A10) was
inserted upstream of viral genomic 5V-terminal sequences in fragment A. Restriction enzyme sites used for cloning are listed below the fragments. (B) cDNA
fragments with the consensus amino acid sequence were selected for assembly of the full-length clone in pBR322. An AclI site was incorporated immediately
downstream of the poly(A) tail. The artificially introduced genetic marker, a BsrGI restriction enzyme site at position nt 1170, is shown. Bent arrow shows the
position and direction of transcription by T7 RNA polymerase. (C) Original bacterial stock carrying pFL12 was propagated six times in E. coli DH5a. Plasmid
DNA from passage 1 (P1) and 6 (P6) bacterial cultures was extracted, digested with MfeI, and resolved by electrophoresis on a 0.9% agarose gel along with a
size marker (M). Expected sizes of the products of digestion are 1525, 1704, 1882, 1906, 2617, 4527, and 5034 bp. Gel image is inverted.
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that 40 adenosine residues at the 3V terminus of the viral
genome were sufficient to recover infectious virus, we
incorporated a poly(A) tail of 41 residues at the 3V end ofTable 1
Primers used in the present study
Primer Sequencea
For fragment A
P1F 5VGCATATAAGCTTTAATACGACTCACTATAG
P1146R 5VGTGTCAGTCGACGTAGATGTACAACGA
T7P+ 1 5VATATAAGCTTCGGACCGTAATACGACTCA
TCTATGCCATGACATTTGTATTG
For fragment B
P1145F 5VGTGTCAGATATCTGTACAGTACTTCTCT
P6154R 5VGTGTCAGATATCAGCCCATATGTCTTTA
For fragment 5C
P5706F 5VATATAGATATCGCACATGTCCTTACGGG
P9791R 5VATATAGATATCCATCTAGAGGGCTTGTG
For fragment 3C
P9783F 5VATATAGGATCCCTCTAGATGAGGTGTT
P13625R 5VATATAGGATCCCTTGACATGTTGGACG
For fragment D
P12687F 5VGTGTCAAAGCTTGTACATTCCTCCATAT
P15393RpolyA 5VGTGTCAGTCGACGCGTTTTTTTTTTTTT
TTTT TTTTTTTTTTTTTAATTTCGGCCG
For genetic tag
P24F 5VTGCCTCGGCATTTGTATTGTC
P1763R 5VCACATTCAAGGGGGAGCAGAGAAG
a T7 RNA polymerase promoter sequence is italicized. Underlined sequences re
assembly. PRRSV-specific sequences are in bold-face type.
b Nucleotide position within the NVSL#97-7895 PRRSV isolates consensus full-fragment D. Further details of the construction of the full-
length cDNA clone have been described in Materials and
methods. Clones were screened to ensure insertion of frag-
ments in the correct orientation, and three full-length cDNAViral genome
positionb
GTGCCTCGGCATTTGTATTGTCAGG 24–47
TAGGCCCATC 1155–1174
CTATAGGATGACGTATAGGTGTTGGC 1–42
G 1169–1185
ATTATGTGGC 6157–6178
5730–5746
C 9798–9815
G 9805–9823
TAGC 13640–13660
TTTCCTCC 12710–12734
TTTTTTTTTTT
CATGGTTCTCGC
15391–15454
24–44
1741–1764
present restriction enzyme recognition sites utilized in full-length cDNA
length genome.
Fig. 2. Rescue and passage of PRRSV. (A) MARC-145 cells were
transfected with in vitro transcripts derived from pFL12Pol or pFL12, or
with total RNA from cells infected with parental virus. At 2 days
posttransfection, cells were examined for expression of N protein by
immunofluorescence. (B) Supernatants from parallel cultures of transfected
cells were collected 2 days posttransfection, clarified, and passaged onto
naı¨ve MARC-145 cells. Forty-eight hpi, the cell monolayer was examined
for expression of N protein as before. Cells in panel B were photographed at
higher magnification than in panel A.
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full-length cDNA clones contained serine and proline res-
idues at amino acid positions 1028 and 2783 in ORF1ab
polyprotein, respectively, because these amino acids were
predicted in the consensus sequence of the viral genome.
Sequence of all three full-length clones matched completely
with the consensus parental viral sequence at the amino acid
level. One clone, pFL12 (Fig. 1B), was used in the studies
reported here. Also, polymerase-defective mutant template,
pFL12Pol, was generated by alteration of the catalytic
domain of the polymerase from SDD to AAA. This template
served as the negative control in our studies. During the
cloning process, we introduced a BsrGI site at nt1170,
which served as the genetic marker (Fig. 1B), as it was
not present in the parental virus genome at that position.
In a previous report (Meulenberg et al., 1998), certain
variants of the full-length cDNA clone of PRRSV were
found to be unstable when propagated in E. coli DH5a.
Although all of our subclones, as well as the full-length
cDNA clone in pBR322 vector, were stable during initial
passages in E. coli DH5a, we wanted to ensure that our
plasmid (pFL12) containing the full-length cDNA of
PRRSV genome was stable during further passages. The
original bacterial stock carrying pFL12 was serially pas-
saged six times. The plasmid from the original culture and
the sixth passage culture was recovered and subjected to
restriction digestion with MfeI, which recognizes seven sites
within the viral genomic cDNA in the plasmid. Electropho-
retic analysis of the digestion products in an agarose gel
shows identical DNA banding patterns (Fig. 1C) for plas-
mids obtained from the two passages. This result demon-
strates that the pFL12 plasmid is stable during propagation
in E. coli DH5a cells.
Rescue of cloned PRRSV from in vitro transcripts
The plasmids, pFL12, and pFL12Pol were linearized by
restriction with AclI and used for in vitro transcription by T7
RNA polymerase to synthesize capped RNAs. Synthesized
full-length transcripts possessed two nonviral guanosine
residues at the 5V terminus of the transcripts. In addition,
the 3V terminus would be expected to contain a poly(A) tail
of 43 adenosine residues: 41 from the RT-PCR amplicon
and 2 from the restricted AclI site.
Previous studies with the LV and VR-2332 infectious
cDNA clones utilized BHK-21 cells for transfection of
genome length capped RNAs and virus recovery (Meulen-
berg et al., 1998; Nielsen et al., 2003). Our preliminary
studies indicated that MARC-145 cells could be electro-
porated with RNA for recovery of infectious PRRSV as
efficiently as BHK-21 cells. In subsequent studies, we have
used MARC-145 cells for the rescue of PRRSV by trans-
fection of in vitro transcripts and also for virus propagation.
Two days following transfection of MARC-145 cells with
in vitro transcripts or RNA from virus-infected cells, cells
were examined by fluorescence microscopy for expressionof nucleocapsid (N) protein. Results (Fig. 2A) show that
about 5% of cells transfected with FL12 RNA expressed the
N protein. Although overall transfection efficiency of intact
genome length transcripts was low, the detection of N protein
indicated that MARC-145 cells were indeed transfected and
that these transcripts were translated and replicated leading
to the synthesis of sgmRNAs, particularly, ORF7 N
sgmRNA. Immunofluorescent analysis of transfected cells
suggested that on average, 20000 infectious centers per
microgram of cDNA-derived full-length in vitro transcripts
were seen. Cells transfected with FL12Pol RNA did not
express the N protein as evidenced by the absence of
fluorescent cells. Approximately 2% of cells transfected with
parental viral RNA expressed the N protein. Expression of N
protein in parental viral RNA transfected cells likely origi-
nated from both input ORF7 sgmRNA and from replication
of genomic RNA followed by de novo transcription of ORF7
sgmRNA.
At 48 h posttransfection, supernatants from parallel
cultures of transfected cells were collected and used to
infect naı¨ve MARC-145 cells. Immunofluorescence exam-
ination of infected cells at 2 dpi (Fig. 2B) showed high
levels of expression of N protein indicating that viable and
infectious PRRSV was rescued from the cells transfected
with in vitro transcripts. Cells infected with supernatant
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protein expression. In addition, cells inoculated with super-
natant, derived from parental and FL12 RNA transfected
cells, displayed cytopathic effects (CPE) within 2–3 dpi. No
CPE was observed in cells inoculated with supernatant from
FL12Pol RNA transfected cells. Titration of PRRSV in
supernatants collected from transfected and passage one
cells showed average titers of 105 and 106 PFU/ml, respec-
tively. One additional passage of the culture supernatant
resulted in growth of vFL12 to titers reaching about 4  107
PFU/ml, which is similar to that obtained with the parental
virus. We also observed that vFL12 could infect PAMs (Fig.
3B), indicating that the recombinant virus possessed bio-
logical characteristics of the parental virus. Thus, our results
show that fully viable and infectious virus was recovered
from MARC-145 cells transfected with capped in vitro
transcripts derived from a PRRSV full-length cDNA clone.
Characterization of the cloned virus
During assembly of the genome length cDNA, we
engineered a genetic marker, a BsrGI site at nt 1170, to
distinguish vFL12 from the parental virus. To determine if
the rescued virus was derived from in vitro transcripts, we
amplified a 1740 bp DNA fragment, encompassing the
genetic marker, from RNA of infected cells and examined
for the presence of the BsrGI site. Results show that the
amplified DNA from vFL12-infected sample contained the
BsrGI site as it was digested with the enzyme to generate
two fragments (Fig. 3A). As expected, amplified DNA from
the parental virus-infected sample did not contain the BsrGI
site. These results indicate that virus rescued from FL12
RNA transfected cells was indeed derived from FL12 RNA
and not from contamination by parental virus.Fig. 3. Characterization of rescued virus. (A) An amplicon of 1740 bp, spanning
infected with either vFL12 (lanes 3 and 4) or parental virus (lanes 5 and 6). pFL12 D
The amplicons were digested with BsrGI. DNAwas electrophoresed on 1% agaros
parental virus. MARC-145 cells (2.5  106) were infected with either vFL12 or par
by plaque assay. PAMs were infected and cultures were collected at 6, 12, and 24
replica experiments.To compare the growth of vFL12 and parental virus in
MARC-145 cells, we performed growth kinetics studies on
confluent monolayers containing a total of 2.5  106 cells.
Results (Fig. 3B) show that growth kinetics of vFL12 and
parental virus was not significantly different from each other
and that titers peaked at 48 hpi for both viruses. The
maximum titers of vFL12 reached 4  107 PFU/ml, whereas
the parental virus grew to a peak titer of about 8  107 PFU/
ml. These studies indicate that vFL12 possesses growth
characteristics similar to the parental virus. Infection of
PAMs (Fig. 3B) also indicated that vFL12 replicated with
similar growth kinetics as the parental virus, although peak
titers for both viruses were lower than those obtained with
MARC-145 cells. The lower peak titer of both viruses in
PAMs is most likely because we used significantly fewer
numbers of PAMs in these experiments as compared with
the MARC-145 cells. Furthermore, PAMs exhibited signif-
icant cytopathic effects and cell death by 24 hpi and
therefore, culture supernatants beyond this time point were
not used for growth kinetics studies.
Primer extension analysis of the cloned virus genome
The in vitro transcripts used to rescue infectious vFL12
contained two nonviral guanosine residues at the 5V termi-
nus. Previous studies with infectious cDNA clones of RNA
virus genomes (Boyer and Haenni, 1994) suggest that 5V
terminal nonviral nucleotides sometimes are not tolerated by
viral polymerases and lead to severe attenuation or obliter-
ation of viral replication. To analyze whether PRRSV
polymerase would correct the nonviral nucleotides during
replication, we infected MARC-145 cells with vFL12 or
parental virus, and primer extension was performed using
RNA from infected cells or using in vitro transcripts asthe genetic marker, was amplified by RT-PCR using total RNA from cells
NA also was used in PCR amplification as a positive control (lanes 1 and 2).
e gel and an inverted image was acquired. (B) Growth kinetics of cloned and
ental virus. At 6, 12, 24, 48, and 72 hpi, supernatant was collected and titrated
hpi for titration of infectivity. Error bars represent standard deviation from
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expected, predominantly contained two guanosines and
the cap, which is extended by reverse transcriptase during
primer extension (Fig. 4, lane 6). The products from vFL12
RNA (lane 7) were two nucleotides shorter than the in vitro
transcripts but were of the same size as those obtained with
the parental virus (lane 8). These results indicate that the
PRRSV RNA polymerase corrected the additional residues
at the 5V terminus during replication of the transfected in
vitro transcripts.
Experimental infection of young pigs with the cloned virus
results in vigorous replication in vivo and induction of frank
clinical symptoms
Upon inoculation, both vFL12- and parental virus-inoc-
ulated groups developed symptoms of PRRS similar to those
typically described when young pigs are inoculated with a
virulent strain of PRRSV (Rossow et al., 1995). These
symptoms were expressed in our experiment by lethargy,
lack of appetite, roughness of hair coat, occasional sneezing,
some coughing, and some diarrhea most of which started
within 48 h postinoculation. The intensity and duration of the
symptoms seemed to correlate closely with the kinetics of the
development and the intensity of hyperthermia (Fig. 5A).
The vFL12-inoculated group exhibited a hyperthermic peak
that was significantly higher (P < 0.05) than the temperature
baseline in the sham-inoculated control group, specifically
from days 3 to 6 postinoculation. Interestingly, in the
parental virus-inoculated group, which also developed some
degree of hyperthermia, the thermal peak was less promi-Fig. 4. Nonviral 5V guanosine residues in the in vitro transcripts from pFL12
are corrected by PRRSV polymerase during RNA replication. Primer
extension analysis of RNA, isolated from cells mock-infected (lane 5) or
infected with vFL12 (lane 7) or parental virus (lane 8) or capped in vitro
transcripts alone (lane 6), was performed using a negative-sense
oligonucleotide. Lanes 1–4 show the sequence ladder obtained with the
same oligonucleotide using pFL12 DNA template. Nucleotides marked by
* correspond to migration positions of extended cDNAs due to addition of
cap. Arrow and arrowhead show the positions of 5Vends of in vitro
transcripts and replicating viral RNAs, respectively.nent, modestly rising above the normal temperature curve
registered for the sham-inoculated group. The symptoms
exhibited by the vFL12-inoculated group were the more
prominent of the two groups as observed by the amount of
food left unconsumed or the degree of alertness of the
animals. In addition, the higher severity of the disease
observed in the vFL12-inoculated group was further
evidenced by the fact that one of the animals died of typical
secondary complications to PRRSV infection at 23 dpi. A
necropsy and diagnostic workup on this animal showed
immunohistochemical detection of PRRSV in several tissues
and histopathological lesions suggestive of colonization by
Streptococcus suis or Salmonella. Infectious vFL12 was
isolated from multiple tissues, including lymph nodes, lung,
spleen, and kidney. The parental virus-inoculated group
exhibited milder symptoms of infection although the sham-
inoculated control group remained healthy during the study
period.
Based on the time points postinoculation that we used to
follow the viremia profile, it can be inferred that the peak of
infectious PRRSV titer in blood must have occurred during
the first week postinoculation, with an ensuing sustained
and slow decay afterwards, which is typical of infection
with virulent strains of PRRSV (Fig. 5B) (Yoon et al.,
1996). By the end of the observation period at 22 days
postinoculation, a detectable viremia, a titer above the 101.5
TCID50/ml detection threshold of the assay, was still evident
in two of the animals of the vFL12-inoculated group and in
three animals of the parental virus-inoculated groups. Fur-
ther evidence of in vivo replication was obtained by analysis
of the PRRSV specific seroconversion, as indicated by the
curve of S/P ratios from the commercial Idexx ELISA kit.
Although both antibody curves (Fig. 5C) indicate occur-
rence of a robust PRRSV replication, it should be noted that
the response in clone inoculated group was significantly
higher (P < 0.05).
The cloned virus is genetically stable and transmitted
horizontally to uninfected animals
From the viremic serum samples of the two PRRSV
inoculated groups at 14 days postinoculation, RNA was
extracted and RT-PCR was performed to amplify the 1740
bp amplicon to ascertain whether or not the BsrGI genetic
marker was present. Results show that the amplicon
contained the BsrGI site in the vFL12-inoculated group
(Fig. 5D, left panel) that should be expected if the virus’
genotype was stably maintained throughout the multiple
rounds of replication that occur in vivo. Virus isolated
from the parental virus-inoculated pig did not contain the
BsrGI site. When two sentinels were introduced at day 19
postinoculation into the group infected with vFL12, rapid
horizontal transmission occurred. Virus was detected in
one sentinel within 3 days of contact although both
sentinels were viremic by day 8. On the other hand, the
parental virus was transmitted only after 3 weeks of
Fig. 5. The cloned virus retains in vivo markers of virulence and is genetically stable. Three groups of pigs (four pigs per group) were sham-inoculated or
inoculated with either vParental or vFL12 at TCID50/ml of 10
5.2 and 104.8, respectively. (A) Temperatures were recorded daily from 2 days before inoculation
to 16 dpi. Average temperatures from four different animals in each group are shown. (B) Serum samples were collected at 4, 7, 14, and 22 dpi and virus titers
were determined and expressed as TCID50/ml. Values represent average titers from four animals. (C) Serum antibody titers were determined with the Idexx
ELISA kit. Values represent average titers from four animals. Dashed line at 0.4 S/P ratio designates threshold value above which titers are considered positive
for anti-PRRSVantibodies. Error bars in panels A, B, and C represent standard deviation. (D) Serum from 14 dpi, recovered from inoculated animals, was used
to distinguish between vFL12 and vParental by examining for the presence of the BsrGI genetic tag (left panel). Viral RNA extracted from sera was amplified
by RT-PCR and the products were digested with BsrGI. Similar analysis (lane 7) was performed with virus in serum from a sentinel pig at 8 days
postcohabitation with pigs infected with vFL12 (right panel). Gel image is inverted. Error bars represent standard deviation.
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virus as being vFL12 was unequivocally demonstrated by
the presence of the genetic marker (Fig. 5D, right panel),
thus confirming that the genetic stability of the cloned
virus is a feature maintained both within and between
animals.Discussion
In this report, we describe the complete nucleotide
sequence of the viral genome and the construction of
infectious cDNA clone, FL12, for a highly pathogenic,
North American isolate of PRRSV. Transfection of capped
in vitro transcripts, derived from this clone, directly into
MARC-145 cells led to efficient recovery of infectiousvirus from cultured cells. Indeed, at day 5 posttransfec-
tion, CPE was observed in transfected cells. Robust
recovery of the virus was further evident by detection of
CPE in cells infected with culture supernatant from trans-
fected cells. Cloned virus, vFL12, displayed similar
growth properties to its parent virus in MARC-145 cells,
in PAMs, and in the animal host. More significantly,
animal studies showed that vFL12 and the parental virus
rescued from cultured cells induced similar patterns of
viremia and seroconversion. Furthermore, we observed
horizontal transmission of vFL12 from infected to sentinel
pigs by as early as day 3 after cohabitation. Detection of
the BsrGI genetic marker indicates that vFL12 remained
genetically stable during passage in cells, multiple rounds
of replication in inoculated pigs, and after secondary
transmission to sentinel pigs.
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America and Europe, PRRSV has become endemic in
virtually every swine farming nation and has emerged as
a significant economic menace within the swine industry.
The most feasible approach to thwarting the virus exists in
vaccination. Production of first generation vaccines has
resulted in wide immunizations on both continents. How-
ever, it is becoming evident that currently available vac-
cine strains are unstable and sometimes revert to virulent
phenotypes in vaccinated animals (Key et al., 2003;
Mengeling et al., 1999; Nielsen et al., 2002; Opriessnig
et al., 2002). Thus, development of vaccine strains from
multiple passages in tissue culture may not be effective.
Rather development of attenuated strains through reverse
genetics manipulation of viral full-length recombinant
cDNA clones would provide greater predictability in
phenotype outcome and host immunization efficacy. With
the advent of infectious cDNA clones for Lelystad virus
and VR-2332, such studies will be possible. Here, we have
reported the development of an infectious cDNA clone for
a highly pathogenic North American strain of PRRSV that
appears to resemble its parent strain, closely, in terms of its
growth and pathogenic properties. This reagent will play
an important role in our endeavor toward understanding
the determinants of virulence of this significant swine
pathogen.
Sequence determination showed a 91% identity between
NVSL #97-7895 and VR-2332, indicating that NVSL #97-
7895 is a distinct isolate. Interestingly, the consensus
sequence of the full-length genome contained a two-base
insertion in the 5V UTR at nt 90 and nt 129 in comparison
to North American isolates VR-2332, PA-8, and 16244B. It
is highly unlikely that these insertions resulted from error
during reverse transcription or from sequencing because
they were present in all sequenced clones derived from two
independent RT-PCR amplifications. Whether such inser-
tions in the 5V UTR of the viral genome influence the
growth and pathogenic characteristics or not remain to be
established.
In the report by Nielsen et al. (2003), recovery of virus
was achieved after multiple passages and CPE was first
observed in passage 3, whereas virus derived from parental
viral RNA displayed CPE as early as passage 1. In addition,
titers recorded for the cloned virus were consistently several
fold lower than that for the parental virus. The authors
speculated that it was possible that incorporation of nonviral
guanosine residues at the 5V terminus of the viral genome
may have contributed to diminished growth capacity of the
cloned virus. However, our primer extension analysis sug-
gests that the viral RNA polymerase possesses inherent
property to correct the 5V-terminal nonviral residues during
replication. The fact that our studies, reported here, demon-
strate robust recovery of infectious PRRSV indicates that the
full-length cDNA with the consensus sequence containing
the combination of amino acids at positions 1028 and 2783
is optimal for growth of the virus.The cloned virus, vFL12, transmits from host-to-host
with high efficiency, therefore, providing the background
for studying the role that individual sequences or genes
may have in transmissibility, a fundamental property of
viral virulence. Such applications of reverse genetics have
already proven highly successful in studying the molecular
basis of transmission in plant (Andrejeva et al., 1999;
McLean et al., 1993), nematode (Vassilakos et al., 2001),
and animal (Luciw et al., 1999) RNA viruses. Likewise,
the properties of vFL12 provide the experimental basis for
a better, more precise discrimination between the attributes
of shedding and attenuation of virulence in future vac-
cines, which would help to correct a defect currently
affecting commercial vaccines. Current classically attenu-
ated PRRSV vaccines are known to shed from the
recipient animal extensively to a level equivalent to that
of wild-type PRRSV (Nielsen et al., 2002; Verheije et al.,
2003).
A remarkable property of vFL12 resides in its robust
immunogenicity, which translates into a vigorous serocon-
version exceeding that of the parental virus. We interpret
that this enhanced serologic titer of vFL12 is due to higher
levels of replication of vFL12 in vivo. This aspect of vFL12
biology, however, should be of cardinal importance to
identify possible dispensable B-cell epitopes that may serve
as significant serological markers for future vaccines. Exam-
ples of potentially deletable sequences that could serve for
the development of marker vaccines were recently reported
to map throughout ORF1a in nsp2, ORF3, and ORF4
(Oleksiewicz et al., 2001).
The apparent enhancement of infectivity and virulence in
vFL12 over the parental virus is remarkable. It has been
known for some time, from other cDNA clone systems, that
some infectious transcripts appear to be more infectious than
the corresponding parent virus (Hamilton and Baulcombe,
1989; Hayes and Buck, 1990). In these cases, the occurrence
of this enhanced virulence was associated with possible
mutations favoring infectivity. However, a remarkable as-
pect of our experiment is that vFL12 precisely corresponds
to the prevailing consensus sequence. Our in vitro and in
vivo data, specifically enhanced growth of vFL12 in
MARC-145 cells and macrophages, clinical signs (i.e.
hyperthermia), enhanced ability to excrete through mucous
membranes and transmit to uninfected sentinels, and im-
mune response kinetics, suggest that vFL12 may represent
one of the most virulent populations within quasispecies of
the parental virus.
Overall, vFL12 replicates efficiently in cell culture, in
macrophages, and in the natural host. Therefore, we believe
that this provides a significant tool, through a systematic
site-specific mutagenesis approach, to examine the determi-
nants of virulence and attenuation based on differential
replication in cell lines, on the one hand, and in cultured
PAMs and the natural host, on the other hand. This will have
significance in development of safer, more efficacious
replicating vaccines against PRRSV.
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Virus and cells
PRRSV NVSL #97-7895 was isolated in 1997 in south-
eastern Iowa from a vaccinated herd on a farm that was
experiencing severe reproductive failure in pregnant sows.
The virus was passaged up to five times on MARC-145
cells, which were maintained in Dulbecco’s Modified
Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and antibiotics (100 units/ml penicillin,
20 Ag/ml streptomycin, 20 Ag/ml kanamycin). In vitro
transcripts were electroporated into MARC-145 cells, which
were also used for virus rescue and titration experiments.
BHK-21 cells were maintained in Earle’s MEM with 5%
FBS and antibiotics and were used in initial transfection
studies for recovery of virus from in vitro transcripts.
Porcine alveolar macrophages (PAM) were extracted by
lung lavage of 4-week-old piglets free of PRRSV, following
a published protocol (Mengeling et al., 1996). Isolated
PAMs were maintained in RPMI medium with 10% FBS
at 37 jC and 5% CO2.
Extraction of viral RNA
Fifth passage virus grown on MARC-145 cells was
collected from culture supernatant and pelleted by ultracen-
trifugation at 100000  g through a 30% sucrose cushion.
The virus pellet was resuspended in phosphate-buffered
saline (PBS) and viral RNA was extracted with TRIzol LS
(Invitrogen) using the manufacturer’s protocol. The final
RNA pellet was resuspended in water and stored at 30 jC
in small aliquots.
Sequence analyses
Five amplicons, designated A, B, 5C, 3C, and D,
spanning the full-length genome, were generated by reverse
transcription (RT) with Superscript III (Invitrogen) and PCR
amplification with Expand HiFidelity Taq (Roche) or Triple
Master Mix (Eppendorf). The amplicons were individually
inserted into pBR322. The primers used in RT and subse-
quent PCR amplification are shown in Table 1. Fragment D
was amplified with primer P15393RpolyA, which incorpo-
rated 41 adenosines at the 3V terminus. Six to 12 clones of
each fragment were sequenced. Using dideoxy-chain termi-
nator sequencing chemistries (Sanger et al., 1977) and an
Applied Biosystems 3730 automated DNA sequencer (PE
Biosystems, Foster City, CA), DNA templates were se-
quenced bidirectionally with forward and reverse primers.
Bases were called using Phred (version 0.020425.c) (Ewing
et al., 1998), which also produced a quality file containing a
predicted probability of error at each base position. DNA
sequences were assembled with Phrap (version 0.990329)
(Ewing and Green, 1998) using the quality files and default
settings to produce a consensus sequence with some manualediting using Consed (version 13) sequence editor (Gordon
et al., 1998).
The 5V terminus of the viral genome was determined by
RNA ligase-mediated rapid amplification of cDNA ends
(RLM-RACE) using the GeneRACER kit (Invitrogen).
Briefly, an RNA oligonucleotide of known sequence was
ligated to viral genomic RNA that had been decapped by
treatment with tobacco acid pyrophosphatase. RT-PCR was
performed with primers that hybridize to known sequences
to generate a fragment, which was cloned in pBR322. Six
clones of this fragment were sequenced on both strands to
establish the consensus.
The consensus sequence of the full-length viral genome
has been deposited in Genbank under accession number
AY545985.
Assembly of full-length cDNA clone
Clones containing the consensus sequences were used
for assembly of the full-length cDNA. Plasmids containing
fragments A and D, representing the genomic terminal
sequences, were combined using a BsrG1 site to form the
plasmid pAD. The 5V terminus of the viral genome was
repaired to integrate the bacteriophage T7 RNA polymer-
ase promoter and the authentic 5V-terminal nucleotides
determined by RLM-RACE. The 3V terminus was modified
to introduce an AclI restriction enzyme site for lineariza-
tion of the template before in vitro transcription. Ligation
and transformation was performed following the standard
procedures described by Sambrook et al. (1989). All
plasmids were propagated in E. coli DH5a. Plasmids
containing fragments 5C and 3C were combined via an
XbaI site and the new recombinant was fused with the
plasmid containing fragment B using a shared Bsu36I site.
This intermediate recombinant plasmid was digested with
BsrGI to release a 12.3-kb fragment, which was cloned
into the BsrGI site of the repaired pAD. The resulting
plasmid, pFL, contained the sequences of the entire viral
genome under the control of T7 RNA polymerase promot-
er in the vector pBR322. Both strands of three full-length
clones were sequenced for accuracy. All three clones
contained the consensus sequences and in vitro transcripts
from all three clones were shown to produce infectious
virus. Clone #12, pFL12, was used in the studies reported
here.
Coincidentally, the cloned BsrGI at nt1170, which was
introduced in the primer for initial PCR amplification, was
not present in the determined consensus sequence for the
parental virus at that position and thus, served as a genetic
marker. A replication defective construct, pFL12Pol, was
generated from pFL12 by nucleotidyl mutation of the
putative catalytic domain of the viral polymerase from
5VTCGGACGAC to 5VGCGGCCGCC, resulting in an SDD
to AAA amino acid change. This construct served as a
negative control in our studies with rescue of PRRSV from
in vitro transcripts.
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pFL12 and pFL12Pol plasmids were restricted with
AclI. Purified, linearized DNAs served as templates for in
vitro transcription of capped RNA using the mMESSAGE
mMACHINE Ultra T7 kit (Ambion) with cap analog. The
reaction mixture was digested with DNaseI to remove
template DNA and subsequently was extracted with phe-
nol–chloroform. RNA was precipitated with an equal vol-
ume of isopropanol and recovered by centrifugation. The
RNA pellet was resuspended in water and stored at 30 jC
in small aliquots. Size, integrity, and concentration of the
capped in vitro transcripts were determined by electropho-
resis under denaturing conditions on a glyoxal agarose gel.
Initial transfections were performed on BHK-21 and
MARC-145 cells. Cells were harvested, washed, and resus-
pended in DMEM containing 1.25% dimethyl sulfoxide at a
concentration of 5  106 cells/ml. Per pulse, 0.4 ml of cell
suspension was used. Ten micrograms of total cellular RNA
from MARC-145 cells infected with parental virus or 5 Ag
of in vitro transcripts along with 5 Ag of uninfected cellular
RNA were added to cells and electroporated at 250 V and
950 AF (Gene Pulser Xcell, Bio-Rad). After electroporation,
the cells were diluted in cell growth medium and 90% of the
cells were seeded in 60-mm plates. The remaining fraction
of cells was seeded in 24-well plates to monitor PRRSV N
protein expression by immunofluorescence. At 16–18
h posttransfection, the cells were washed and incubated in
DMEM with 5% FBS. At 48 h posttransfection, supernatant
was collected and clarified by centrifugation. Ten percent of
the clarified supernatant was used to infect naı¨ve MARC-
145 cells in 35-mm wells. Because virus was rescued from
both cell types, all subsequent experiments were performed
using MARC-145 cells.
Rescue of infectious virus was confirmed by immuno-
fluorescence microscopy for the expression of N protein in
infected cells at 48 h. Cells were fixed in methanol/acetone
(1:1) for 30 min at 20 jC. Fixed cells were incubated with
anti-N monoclonal antibody SDOW17 (National Veterinary
Services Laboratories, Ames, IA) (Nelson et al., 1993) at
1:500 dilution in phosphate-buffered saline (PBS) at 37 jC
for 30 min. After three washes with PBS, cells were
incubated with fluorescein isothiocyanate-conjugated sec-
ondary anti-mouse goat antibody at 37 jC for 30 min.
Finally, cells were washed three times with PBS and
visualized with a Nikon inverted fluorescence microscope
fitted with a camera (Optronics). Transfected cells were
examined for expression of the viral N protein, as described
above.
Detection of genetic marker
MARC-145 cells were infected with cloned, vFL12, or
parental virus at a multiplicity of infection (MOI) of 1. Cells
were harvested with TRIzol (Invitrogen) at 60 h postinfec-
tion (hpi) and total cellular RNA was extracted. Recovered
H.M. Truong et al. / VRNA was reverse transcribed, as described above, using the
primer P1763R, and the cDNA was amplified using the
same RT primer along with a second primer, P24F (Table 1).
When digested with BsrGI, the 1740 bp amplicon, encom-
passing the cloned BsrGI genetic marker, should produce
two fragments of 1146 and 594 bp.
Growth kinetics and characterization
Growth kinetics was examined by infecting MARC-145
cells with vFL12 and parental virus at an MOI of 1. After
1 h of virus adsorption, cells were washed and incubated at
37 jC in virus growth medium. Small aliquots of infected
cell supernatant were collected at various times postinfec-
tion, and virus titers were determined by plaque assay on
MARC-145 cells and expressed as plaque forming unit per
milliliter (PFU/ml). Growth kinetics in PAMs, infected at an
MOI of 10, was determined similarly and the viral titers
were expressed as 50% tissue culture infectious dose per
milliliter (TCID50/ml) and converted to PFU/ml for graph-
ical analysis, using an empirically derived ratio of 1.11 PFU/
ml to one TCID50/ml.
Primer extension
Total RNA, from cells mock-infected or infected with
vFL12 or parental virus, and in vitro transcribed capped
RNAs were used for primer extension. A 32P end-labeled
oligonucleotide of negative-sense polarity, starting at nt 78
of the viral genome, was used in the extension reaction with
Superscript III, as described before. A sequencing ladder
was obtained with pFL12 as template and the same radio-
labeled primer. The primer extension products were ana-
lyzed alongside the sequencing reaction products in a 6%
polyacrylamide gel containing 7 M urea.
Animal experiments
Mixed breed (Duroc  Landrace), recently weaned
pigs, averaging 12 lb weight and 18 days of age, were
obtained from a PRRSV-free farm. The pigs were consis-
tent with negative serology for PRRSV and absent in
clinical history of the disease. Three groups of four
animals were used. One group was inoculated with a total
dose of 105.2 TCID50/2 ml of PRRSV NVSL #97-7895
(parental virus) instilled intranasally (1 ml in each nostril).
Another group was inoculated in a similar manner using a
similar dose of vFL12 (second passage on MARC-145
cells). A third group of animals was sham-inoculated with
cell culture medium (DMEM with 10% FBS). The three
groups of animals were housed in strict isolation from
each other using animal housing facilities compatible with
biosafety level-2 conditions, including negative pressure
environment to prevent any possible cross-infection be-
tween groups. On a daily basis, the animals were clinically
inspected and their body temperatures were recorded from
H.M. Truong et al. / Virology 325 (2004) 308–3193182 days pre- until 16 days postinfection (dpi). Sequential
blood samples were collected from all the animals at 4, 7,
14, and 22 dpi and used to verify levels of viremia and
kinetics of PRRSV-specific antibody development using a
validated commercial ELISA kit (Idexx Labs, Portand,
ME). Blood samples were used to detect PRRSV by
conventional viral isolation on MARC-145 cells, as pre-
viously described (Bastos et al., 2004). Likewise, virus
obtained from viremic sera, from both cloned and parental
PRRSV-inoculated groups, were used for RT-PCR ampli-
fication and analyzed for the presence of BsrGI site that
differentiates the clone from the parental virus. Virus
transmissibility studies were undertaken with each of the
two PRRSV-inoculated groups following a previously
published protocol (Wills et al., 2002). Briefly, at 19
dpi, two additional PRRSV-free animals, homogeneous
with the rest of the animals in size and origin, were
introduced into the two PRRSV-inoculated groups to act
as sentinels of contagion. These animals were sampled
together with the rest of the group for evidence of animal-
to-animal transmission by viremia and PRRSV serology.
Also, in the case of viremia, serum samples were used for
molecular analysis of the genetic marker, as described
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